Novartis AG ADR (NVS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Novartis AG ADR stock (NVS) is currently trading at $150.75. Novartis AG ADR PE ratio is 20.71. Novartis AG ADR PS ratio (Price-to-Sales) is 5.05. Analyst consensus price target for NVS is $146.00. WallStSmart rates NVS as Underperform.
- NVS PE ratio analysis and historical PE chart
- NVS PS ratio (Price-to-Sales) history and trend
- NVS intrinsic value — DCF, Graham Number, EPV models
- NVS stock price prediction 2025 2026 2027 2028 2029 2030
- NVS fair value vs current price
- NVS insider transactions and insider buying
- Is NVS undervalued or overvalued?
- Novartis AG ADR financial analysis — revenue, earnings, cash flow
- NVS Piotroski F-Score and Altman Z-Score
- NVS analyst price target and Smart Rating
Novartis AG ADR
📊 No data available
Try selecting a different time range
NVS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Novartis AG ADR (NVS)
NVS trades 244% above its Graham fair value of $48.62, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Novartis AG ADR (NVS) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, operating margin. Concerns around price/book and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Novartis AG ADR (NVS) Key Strengths (4)
Mega-cap company, among the largest in the world
Every $100 of shareholder equity generates $31 in profit
Keeps $25 of every $100 in revenue as net profit
Strong operational efficiency: $28 kept per $100 revenue
Novartis AG ADR (NVS) Areas to Watch (6)
Earnings declining -11.60%, profits shrinking
Very expensive at 6.0x book value
Revenue growing slowly at 2.20% annually
Very low institutional interest at 7.12%
Paying a premium for growth, expensive relative to earnings expansion
Premium valuation at 5.0x annual revenue
Supporting Valuation Data
Novartis AG ADR (NVS) Detailed Analysis Report
Overall Assessment
This company scores 51/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 4 register as strengths (avg 9.5/10) while 6 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with Return on Equity at 30.80%, Operating Margin at 27.80%, Profit Margin at 24.70%.
The Bear Case
The primary concerns are EPS Growth, Price/Book, Revenue Growth. Some valuation metrics including PEG Ratio (2.54), Price/Sales (5.05), Price/Book (6.04) suggest expensive pricing. Growth concerns include Revenue Growth at 2.20%, EPS Growth at -11.60%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 30.80% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 2.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Market Cap, Return on Equity) and negatives (EPS Growth, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NVS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NVS's Price-to-Sales ratio of 5.05x trades at a 48% premium to its historical average of 3.41x (96th percentile). The current valuation is 10% below its historical high of 5.6x set in Mar 2026, and 162% above its historical low of 1.93x in Feb 2009.
WallStSmart Analysis Synopsis
Data-driven financial summary for Novartis AG ADR (NVS) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Novartis AG ADR operates as a stable business with moderate growth and solid fundamentals. Revenue reached 56.7B with 2% growth year-over-year. Profit margins are strong at 24.7%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 30.8% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 24.7% and operating margin of 27.8% demonstrate strong pricing power and operational efficiency.
What to Watch Next
Dividend sustainability with a current yield of 3.2%. Watch payout ratio and free cash flow coverage.
Debt management: total debt of 37.1B is significantly higher than cash (11.4B). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Novartis AG ADR.
Bottom Line
Novartis AG ADR offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:06:44 AM
About Novartis AG ADR(NVS)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.